**Cover page**

**Full title**: Meta-analysis of the effect of *CYP2B6, CYP2A6, UGT2B7* and *CAR* polymorphisms on efavirenz plasma concentrations**.**

**Short Running title**: Meta-analysis of genetic factors influencing efavirenz pharmacokinetics.

**Authors**: Pedro AYUSO1, Megan NEARY1, Justin CHIONG1 and Andrew OWEN1\*

**Institutional affiliations:** 1Infection Pharmacology Group, University of Liverpool, Liverpool, UK.\*Corresponding author. Department of Molecular & Clinical Pharmacology, University of Liverpool, L69 3GF, United Kingdom. Tel: +44(0)1517948211, Fax: +44(0)1517945656, E-mail: aowen@liverpool.ac.uk

**Meta-Analysis Study**

**Abstract**

**Background**: Efavirenz primary metabolism is catalysed by CYP2B6 with a minor involvement of CYP2A6. Subsequently, phase I metabolites are conjugated by UGT2B7, and CAR has been shown to transcriptionally regulate many relevant enzymes and transporters. Several polymorphisms occurring in the genes coding for these proteins have been shown to impact efavirenz pharmacokinetics in some but not all studies.

**Objectives**: A meta-analysis was performed to assess the overall effect of CYP2B6 rs3745274, CYP2A6 (rs28399454, rs8192726 and rs28399433), UGT2B7 (rs28365062 and rs7439366) and NR1I3 (rs2307424 and rs3003596) polymorphisms on mid-dose efavirenz plasma concentrations.

Methods: Following a literature review, pharmacokinetic parameters were compiled and a meta-analysis for these variants was performed using Review Manager and OpenMetaAnalyst. A total of 28 studies were included.

**Results:** Unsurprisingly, the analysis confirmed that individuals homozygous for the T allele for CYP2B6 rs3745274 had significantly higher efavirenz concentrations than those homozygous for the G allele (WSMD = 2.98 [2.19, 3.76] P < 0.00001). A subgroup analysis confirmed ethnic differences in frequency but with a similar effect size in each ethnic group (P = 0.96). Associations with CYP2A6 and UGT2B7 variants were not statistically significant, but T homozygosity for CAR rs2307424 was associated with significantly lower efavirenz concentrations than in C homozygotes (WSMD = -0.32 [-0.59, -0.06] P = 0.02).

**Conclusions:** This meta-analysis provides the overall effect size for the impact of CYP2B6 rs3745274 and CAR rs2307424, on efavirenz pharmacokinetics. The analysis also indicates that some previous associations were not significant when interrogated across studies.

**Introduction**

HIV is one of the world’s most serious health and development challenges. In 2017, there were 36.9 million people living with HIV and around 2.5% people died from AIDS-related illness. Despite increased access to antiretroviral therapy; it is still only available to around 53% of infected people.1 Efavirenz (600mg once daily) has been a cornerstone of first-line antiretroviral therapy for the last two decades and is still often used in certain contexts,2, 3 with a number of studies demonstrating the applicability of its use at a lower dose (400mg) during pregnancy and TB co-infection.4, 5 Efavirenz is metabolised mainly in the liver (90%) through the cytochrome P450 (CYP) system. CYP2B6 is responsible for efavirenz hydroxylation, which produces 8-hydroxyefavirenz, whereas CYP2A6 catalyses formation of 7-hydroxyefavirenz.6 Efavirenz phase II metabolism includes the production of oxidised efavirenz metabolites produced through conjugation by UDP-glucuronosyltransferase (UGT). Furthermore, efavirenz can be conjugated directly to efavirenz-N-glucuronide by UGT2B7.7

Expression of CYP2B6 shows inter- and intra-individual pharmacokinetic variability. The most studied polymorphism to date is *CYP2B6\*6* defined by the rs3745274 (516G>T) and rs2279343 (785A>G) variants. Both polymorphisms are in strong linkage disequilibrium, and the rs3745274 variant is often studied in isolation.8 Accordingly, the impact of rs3745274 on efavirenz pharmacokinetics has been widely explored in many studies and has been associated with alterations in efavirenz metabolism, pharmacokinetics and toxicity in a variety of populations. Thus, individuals that are homozygous for the T allele have consistently demonstrated higher efavirenz plasma concentrations and a decreased rate of 8-hydroxyefavirenz formation than individuals homozygous for the G allele.9-15

The secondary route of efavirenz metabolism via CYP2A6 has been proposed to be more important in the case of patients homozygous for the T variant for *CYP2B6* rs3745274,16 and accordingly certain CYP2A6 polymorphisms have been demonstrated to effect efavirenz plasma concentrations in some studies. The *CYP2A6* rs8192726 and *CYP2A6* rs28399454 variants (493+23G>T; *CYP2A6*\*9B, and 40850474A>C; *CYP2A6*\*17; respectively) have been significantly associated with higher EFV plasma concentrations in a Ghanaian population.17 Moreover, the *CYP2A6* rs28399433 variant (1093C>T *CYP2A6*\*48) has been reported to be associated with altered efavirenz plasma concentrations.18 However, these associations have not been reported in studies of other African,19, 20 American21 or European populations.22

Recently it was reported that the products of efavirenz phase II metabolism are present in plasma at higher concentrations than the oxidized species produced by phase I metabolism.23 *UGT2B7* rs28365062 and rs7439366 genetic variants (735A>G; *UGT2B7*\*1c and 802T>C; *UGT2B7*\*2, respectively) have been highlighted as contributing to inter-patient variation in efavirenz plasma concentration.17, 24 However, conflicting results have been reported.7, 19

Nuclear receptors such as the constitutive androstane receptor (CAR) are transcription factors that regulate drug metabolism enzymes and drug transporters. 25 The *NR1I3* rs2307424 variant (540C>T) has been associated with altered efavirenz plasma concentrations in Chilean patients21 and early discontinuation of efavirenz therapy in Caucasian patients.26 Furthermore, an association between the *NR1I3* rs3003596 (1089T>C) variant and reduced plasma efavirenz concentration has been suggested.27 However, a more recent extended study in the same cohort did not find a statistically significant association,28 and other studies in African and Caucasian populations have not corroborated these associations.28, 29

The effect of *CYP2A6, UGT2B7* and *NR1I3* genetic variants on efavirenz pharmacokinetic remains controversial. Hence, to evaluate the correlation between these genetic variants and efavirenz plasma concentration, a meta-analysis was conducted to systematically review the published evidence and assess an overall effect of their impact.

**Methods**

*Search strategy and study selection*

This meta-analysis was conducted in line with the statement outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)30 (Table S1). PUBMED was searched until October 2017, without language, publication date or publication status restrictions to identify prospective studies, observational cohort studies, cross sectional studies and randomized controlled trials addressing the association between *CYP2B6, CYP2A6, UGT2B7* or *CAR* polymorphisms and efavirenz pharmacokinetics in HIV positive patients. The following search terms were used: efavirenz, HIV, CYP2B6, CYP2A6, UGT2B7, CAR, SNP, polymorphism, genotype, plasma, concentration and pharmacokinetics. In addition, relevant papers were manually screened to identify potentially relevant studies. Studies were considered for inclusion if (a) they explored the association between *CYP2B6, CYP2A6, UGT2B7, NR1I3* polymorphisms and pharmacokinetics of efavirenz in HIV patients of any age; (b) the pharmacokinetics of efavirenz were expressed as efavirenz concentration in plasma at 12h after dosing (C12) (12 ± 2 h) (c) efavirenz pharmacokinetic parameters were described separately according to different genotypes. The original authors were contacted for more detailed information when the articles that met the inclusion criteria provided insufficient pharmacokinetic data. If there were studies with overlapping subject groups, the study with the highest number of patients was included in the meta-analysis. According to the above criteria, two reviewers evaluated the studies and extracted the data independently. Disagreements between reviewers were resolved by consensus.

*Data extraction*

The following information was collected and included in a data extraction form by one review author and the second author checked the extracted data: (1) the basic characteristics of eligible studies, including first authors name, publication year, patient ethnicity and efavirenz dose. (2) The number of subjects for each genotype for all the polymorphisms. (3) The mean values and standard deviation of efavirenz concentration in plasma at 12h after dosing. All concentrations were expressed in ng/mL. If the studies provided the median (range), minimum and maximum values or 25th and 75th percentile range, the method reported by Wan *et al.* 31 was employed to estimate the mean and standard deviation. Disagreements were discussed and resolved by consensus.

To assess the risk of bias, pairs of reviewers worked independently and determined the adequacy of each study.32 Study design, sample size, reliability of genotypes, population stratification, Hardy-Weinberg equilibrium and definition of outcome were evaluated. Disagreements were resolved through discussion.

The primary analysis compared the mean efavirenz concentration between genotype groups for *CYP2B6, CYP2A6, UGT2B7* and *NR1I3* SNPs. For each SNP, three pairwise comparisons were undertaken: heterozygous genotype vs. homozygous common allele, homozygous rare allele vs. homozygous common allele and heterozygous genotype vs. homozygous rare allele. A secondary analysis was performed to evaluate the effect of the association between *CYP2B6* rs3745274 and efavirenz plasma concentration within different ethnicities. This was conducted through exploring the overall efavirenz plasma concentration according to genotype and ethnicity as well by the *CYP2B6* rs3745274 frequency within each ethnic group.

*Statistical analysis*

Standardized mean difference and 95% confidence intervals were calculated to assess the difference between genotypes in pharmacokinetics of EFV, based on efavirenz concentration in plasma at 12h after dosing. Z-tests were performed to determine the statistical significance of the results. Statistical significance was defined as P < 0.05.

To measure heterogeneity across the included studies the *I2* statistic was used. An *I2* value of 50% or more was considered as a substantial level of heterogeneity, and the random-effects model was conducted. When the *I2* value was lower than 50%, a fixed-effects model was applied. We produced a funnel plot and conducted an Egger’s test to assess the risk of bias across studies. All statistical analysis were performed using Review Manager33, Comprehensive Meta-analysis34 and OpenMetaAnalyst.35

**Results**

Literature search

All studies included patients age ≥18 years, with the exception of two paediatric studies. The dose range in both studies was 200-600mg efavirenz per day. In the case of studies including HIV-positive pregnant women, the efavirenz concentration data used was obtained postpartum. Efavirenz concentration data obtained from patients on tuberculosis treatment were not included in the study.

One hundred and six publications were identified that included the CYP2B6 rs3745274. After screening the titles and abstracts, 67 studies were excluded (reviews, letters, articles not directly assessing the CYP2B6 rs3745274 variant). The full texts of the remaining 39 studies were further evaluated. Twenty studies were excluded due to the following reasons: a focus on associations between CYP2B6 rs3745274 and efavirenz minimum concentration or AUC, use of a dominant or recessive model to study genotypes and absence of standard deviation associated with mean values. Nineteen studies were included in the final meta-analysis (Table 1).

For *CYP2A6*, the same criteria were followed with 42 publications identified, and eight studies included in the final meta-analysis (Table 1). For UGT2B7 genetic variants and their effect on EFV pharmacokinetics, the initial search yielded 21 publications. After reviewing the study selection process, four studies were included in the meta-analysis (Table 1). Sixteen publications were identified for NR1I3 genetic variants and their effect on EFV pharmacokinetics. Using the criteria described above, the final meta-analysis included six studies investigating NR1I3 genetic variants (Table 1). Several original authors were contacted for missing or specific data 17-22, 24, 27-29, 36-39 and 11 replied. 17, 18, 21, 22, 24, 27-29, 36, 37, 39 As a result, twenty four different studies of *CYP2B6*, *CYP2A6*, *UGT2B7* and *NR1I3* polymorphisms were included in the meta-analysis (Table 1). A PRISMA flow chart showing the literature search for each gene is provided in the supplementary materials (Figures S1-S4).30

Effect of the *CYP2B6* rs3745274 *variant on efavirenz concentration in HIV positive patients*

Nineteen studies involving a total of 2,391 individuals were analysed. Of these, 42% were African, 21% Caucasian, 26% Asian and 11% were of other ethnic populations. Through heterogeneity testing (*I2*> 50%) a random effects model was applied to analyse differences in efavirenz plasma concentration between the following genotypes: GG and GT, GG and TT and GT and TT. Following these principles, weighted standard mean differences (WSMD) and 95% confidence intervals (CI) were computed in different groups. Results of this meta-analysis assessing the influence of *CYP2B6* rs3745274 on EFV concentration are presented in Figure 1. The heterogeneity observed may have been due to the variable distribution of genotypes in different geographic areas. The analysis confirmed that individuals with a TT genotype had significantly higher efavirenz concentration than G homozygous patients (WSMD = 2.98 [2.19, 3.76] *P* < 0.00001). Similarly, individuals that were heterozygous had a significantly higher efavirenz concentration than G homozygotes (WSMD = 0.74 [0.29, 1.19] *P* < 0.001), and T homozygotes higher than heterozygotes (WSMD = 1.51 [0.99, 2.02] *P* < 0.00001). Thus, we observed a large effect of TT genotype and a moderate effect of GT genotype on with respect to higher efavirenz concentrations. Therefore, there may be a role for tailored efavirenz dosing in HIV patients according to *CYP2B6* rs3745274 genotype.

The funnel plot and an Egger’s test for this analysis provided evidence of considerable asymmetry due to differences in ethnicity of participants (Figure S5). The stratification by ethnicity was deemed the suitable approach to correct for risk of bias. The funnel plot for each ethnicity and the Egger’s test provided no evidence of bias (Figure S6-S8). To achieve this for African ethnicity, Habtewold A *et al.45* and Mutwa PR *et al.47* studies were excluded.

This subgroup analysis that was performed based on ethnicity detected a significant association being Asian patients who showed higher WSMD values (Figure 1).

The secondary measure showed that the overall frequency of the variant allele for *CYP2B6* rs3745274 was 0.322 (0.281-0.362; Table 2). The subgroup analysis demonstrated differences in the polymorphism frequency within different ethnicities. African *CYP2B6* rs3745274 T homozygotes showed a significantly higher frequency than Asian *P* < 0.0001 or Caucasian individuals (*P* < 0.0001; Table 2). Moreover, this sub-group meta-analysis demonstrated a statistically significant higher EFV concentration in T homozygote patients (Table 2), and this was observed within all ethnicity groups included in the analysis (overall EFV concentration in T homozygotes was comparable between different ethnic groups (*P* value = 0.992; Table 2).

Effect of *CYP2A6 genetic variants on efavirenz concentration in HIV positive patients*

We analysed three different *CYP2A6* polymorphisms, rs28399454, rs8192726 and rs28399433. For *CYP2A6* rs28399454, three studies comprising a total of 468 individuals were analysed (Table 1). A fixed effects model was applied to EFV plasma concentration compared by genotypes GG and GA. Two studies reported a zero frequency for AA genotype.21, 22 Thus, these studies were removed for the GG-AA and GA-AA comparisons. The meta-analysis revealed no statistically significant association between *CYP2A6* rs28399454 and EFV concentration for this comparison (Figure S9). No risk of bias was observed (Figures S10). In addition, following the same procedure, *CYP2A6* rs8192726 was analysed. Two studies involving 403 individuals were included and a random effects model was performed (Table 1). WSMD and 95% confidence intervals (CI) were computed. One study reported the frequency of the AA genotype to be zero.21 The meta-analysis showed no statistically significant effect on EFV concentration (Figure S11). Finally, the effect of *CYP2A6* rs28399433 was analysed through the inclusion of four studies comprising 693 individuals (Table 1). The funnel plot and the Egger’s test indicated a small risk of bias for *CYP2A6* rs28399433 which was corrected by means of Sarfo *et al18* study exclusion (Figure S12). A fixed effect model was performed for all the comparisons. The meta-analysis revealed no statistically significant differences for these comparisons. (Figure S13).

Effect of *UGT2B7 genetic variants on efavirenz concentration in HIV positive patients*

We analysed two *UGT2B7* polymorphisms, rs28365062 and rs7439366. For *UGT2B7* rs28365062, four studies involving 949 individuals were analysed (Table 1). A fixed effect model was performed for AA-GG, AA-AG and AG-GG comparisons. The meta-analysis demonstrated no statistically significant association between *UGT2B7* rs28365062 and EFV concentration for any comparison (Figure S14). Similarly, for *UGT2B7* rs7439366 three studies involving 1,099 individuals were included in the meta-analysis. A fixed effect model was performed for CC-TT and CT-TT comparisons and a random effects model for CC-CT. Although individuals with a TT genotype had a notably lower EFV concentration than homozygotes for the C allele, this difference was not statistically significant (WSMD = -0.23 [-0.49, 0.04]; *P* = 0.09). For the CT-TT and CC-CT comparisons, the meta-analysis did not show a statistically significant association between *UGT2B7* rs7439366 and EFV concentrations (Figure S15). No risk of bias was observed (Figures S16-S17).

Effect of *NR1I3 genetic variants on efavirenz concentration in HIV positive patients*

Two *NR1I3* polymorphisms were analysed, rs2307424 and rs3003596. In the case of *NR1I3* rs2307424, six studies involving 1,330 individuals were included (Table 1). A random effect model was performed for CC-CT and CT-TT comparisons and a fixed effects model for CC-TT. Two of these studies reported zero individuals with TT genotype.28, 29 Therefore, four studies were included in the CC-TT and CT-TT comparisons. The meta-analysis revealed no statistically significant differences for CC-CT and CT-TT comparisons. However, when comparison was performed between TT and CC subjects, the meta-analysis indicated that individuals with a TT genotype had a significantly lower EFV concentration than individuals homozygous for the C allele (WSMD = -0.32 [-0.59, -0.06] *P* = 0.02; Figure 2). Hence, a moderate effect of TT genotype on lower efavirenz concentrations was observed. The rs2307424 is associated with a CAR gain of function and would therefore be expected to result in higher CYP2B6 activity and lower efavirenz concentrations.

For the *NR1I3* rs3003596 polymorphism, three studies comprising of 440 individuals were analysed (Table 1). Following the same procedure, a random effect model was performed for TT-CC and CT-CC comparisons and a fixed effects model for TT-CT. The meta-analysis showed no statistically significant differences for any comparisons (Figure S18). No risk of bias was observed (Figures S19-S20).

**Discussion**

Variability in efavirenz plasma concentrations influence its safety and efficacy.14 Genetic polymorphisms in drug metabolizing enzymes, including CYP2B6, CYP2A6 and UGT2B7 and transcriptional regulators such as CAR have been shown to effect efavirenz pharmacokinetics. However, some associations have yielded conflicting results between studies. Therefore, we performed a meta-analysis to systematically assess previously reported associations and provide further clarity on the relevance of *CYP2B6, CYP2A6, UGT2B7* and *NR1I3* polymorphisms.

A large number of *CYP2B6* SNPs have been identified,54 but rs3745274 and rs2839949 (983T>C) have been most extensively studied for their impact upon efavirenz pharmacokinetics. *CYP2B6* rs2839949 is exclusively found in patients of African ancestry. This polymorphism produces an amino acid change in the CYP2B6 protein, resulting in a reduction in enzyme function and subsequently an alteration in efavirenz pharmacokinetics.28, 36, 55, 56 *CYP2B6* rs2839949 and rs3745274 have been reported to explain 8% and 19% of EFV variance, respectively, in a South African population.57 However, *CYP2B6* rs2839949 was not included in the current analysis because the aim was to characterise the effect of *CYP2B6* polymorphisms within multiple ethnic groups. For this reason, *CYP2B6* rs3745274 was the focus of the analysis.9-15 This meta-analysis demonstrates that individuals with a TT or GT genotype had a significantly higher efavirenz concentration than patients homozygous for the G allele in a gene-dose dependent manner, and is in concordance with a previous meta-analysis conducted with a fewer number of studies.58 African *CYP2B6* T homozygotes had a significantly higher frequency than Asian or Caucasian individuals, but the effect of this genotype on EFV plasma concentration was similar between different ethnicities. These results reinforce the important role of *CYP2B6* rs3745274 on efavirenz pharmacokinetics, variability in which has been associated with central nervous system side effects and virological failure.59

A reduced dose of 400 mg efavirenz was demonstrated to be non-inferior to the standard 600 mg dose in the ENCORE 1 trial. Moreover, adverse events related to efavirenz were more frequent in recipients of 600 mg efavirenz than 400mg.60 Recent data have suggested that 400mg doses may be appropriate during therapy with rifampicin during TB coinfection and during pregnancy.4, 5 A *CYP2B6* genotype-guided efavirenz dose reduction in pregnant women also suggested keeping the standard 600 mg dose for fast and intermediate metabolisers while reducing to 400 mg in slow metabolisers.61 Given that the magnitude of effect of *CYP2B6* rs3745274 is similar between different ethnicities, the appropriateness of rolling out validated clinical strategies across populations is derisked.

The effect of *CYP2A6* rs28399433 on efavirenz pharmacokinetics was associated with individuals with concomitant *CYP2B6* slow metaboliser genotypes.24, 62 However, this effect has also been described in individuals independent of *CYP2B6* genotypes and extended to *CYP2A6* rs8192726 and rs28399454 with some conflicting results.17-21 The findings of current meta-analysis indicate no significant effect of *CYP2A6* rs8192726, rs28399433 and rs2839945. However, it should be noted that only a comparatively small number of studies have investigated *CYP2A6*, and the frequency of these SNPs is somewhat lower than *CYP2B6* alleles.

This meta-analysis also failed to find an association between *UGT2B7* rs28365062 and efavirenz concentrations. The association with this genetic variant was also initially described in individuals with *CYP2B6* slow metabolisers genotypes.24 However; all the studies included in our analysis researched the effect of this polymorphism independently of *CYP2B6* status. In addition to rs28365062, we also analysed the effect of *UGT2B7* rs7439366, which was previously associated independently with alterations in efavirenz pharmacokinetics.17 The meta-analysis also did not find a statistically significant effect although individuals with a TT genotype had lower efavirenz concentrations than patients that were homozygous for the C allele. Again, these observations should be interpreted in the context that very few studies have been conducted, and this association was only identified in a Ghanaian cohort.17

CAR is a ligand-activated transcription factor but also regulates expression of *CYP2B6* and other genes in a constitutive manner.63 *NR1I3* rs2307424 has been associated with low efavirenz concentrations in Chilean HIV patients,21 but other studies in African or Caucasian populations failed to demonstrate the association.29, 52 However, the presented meta-analysis suggests that individuals with a TT genotype have significantly lower efavirenz concentrations than individuals that are homozygous for the C allele. This is in line with the association reported between *NR1I3* rs2307424 CC genotype and early discontinuation on efavirenz treatments.26 Neuropsychiatric side effects in patients on efavirenz treatment that lead to early discontinuation have been associated with high plasma concentrations,64-66 and *NR1I3* rs2307424 CC genotype is linked to higher efavirenz plasma concentrations.

This polymorphism is synonymous (proline/proline)67 and there is a lack of functional studies that have sort to show how this SNP might affect CAR functionality. *NR1I3* rs2307424 TT could be in linkage disequilibrium with an undefined causative polymorphism that evokes an increase in CAR activity; this would result in elevated CYP2B6 activity and consequently lower EFV concentrations.

Conversely, *NR1I3* rs3003596 has been suggested to increase CAR expression and therefore elicit an effect through promoting expression of enzymes that participate in efavirenz metabolism.27 However, our meta-analysis failed to demonstrate a definitive correlation between *NR1I3* rs3003596 and efavirenz concentrations. The initial report of this association was conducted in a small cohort28 and other studies including this SNP are scarce. Therefore, further researches to clarify the role of this polymorphism are required.

There are limitations to this meta-analysis. Firstly, the mean and SD values were unavailable in several studies and some of these were excluded from analysis because attempts to contact the authors failed. Secondly, the sample size for some polymorphisms was small. Thirdly, most eligible studies were conducted in African and Asian population while few were conducted in Caucasians.

In conclusion, this meta-analysis reinforces the well reported effect of *CYP2B6* rs3745274 on efavirenz plasma concentrations across different ethnicities. Despite the different allele frequencies observed within different populations, the effect size for the *CYP2B6* rs3745274 is similar. A significant association between *NR1I3* rs2307424 and lower efavirenz concentrations was also reinforced by the meta-analysis, but no association between *CYP2A6* or *UGT2B7* genetic variants was evident.

**Acknowledgment**

We thank Dr. Awewura Kwara, Dr. Sandra G Heil, Dr. David W. Haas, Dr. Collet Dandara, Dr. Adeniyi Olagunju, Dr. Andrzej Bienczak, Dr. Uriel S. Sandkovsky , Dr. David R. Chadwick and their working team for providing us with the additional data required from their studies.

**Funding**

This work was funded by internal budgets at the University of Liverpool.

**Transparency declarations**

AO has received research funding income from ViiV Healthcare, Merck, and Janssen, as well as consultancies from ViiV Healthcare and Merck. He is also a co-inventor of patents relating to the use of nanotechnology in delivery of drugs including efavirenz and other agents, and is a director of Tandem Nano Ltd. Other authors have nothing to declare.

**Table and Figure Legends**

**Table 1**. Basic information of all studies included in the meta-analysis to investigate the effect of *CYP2B6, CYP2A6, UGT2B7* and *NR1I3* polymorphisms over efavirenz pharmacokinetic.

**Table 2**. Subgroup analysis of the *CYP2B6* rs3745274 frequency and its effects over efavirenz concentration through African, Asian and Caucasian populations.

**Figure 1**. Forest plots of the association between *CYP2B6* 516GT and efavirenz plasma concentration. (A) GTvsGG (B) TTvsGG (C) TTvsGT. The center of each square represents the WMD. The area of the square is the number of sample and thus the weight used in the meta-analysis, and the horizontal line indicates the 95% CI

**Figure 2**. Forest plots of the association between *NR1I3* rs2307424 and efavirenz plasma concentration . (A) CCvsCT (B) CCvsTT (C) CTvsTT. The center of each square represents the WMD. The area of the square is the number of sample and thus the weight used in the meta-analysis, and the horizontal line indicates the 95% CI

**Supplementary information**

**Supplementary Material.** Full electronic search strategy.

**Table S1.** PRISMA checklist.

**Figure S1.** Flow chart of *CYP2B6* study according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).

**Figure S2.**  Flow chart of *CYP2A6* study according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).

**Figure S3.** Flow chart of *UGT2B7* study according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).

**Figure S4**. Flow chart of *NR1I3* study according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).

**Figure S5**. Funnel plot for the *CYP2B6* rs3745274 meta-analysis. A) GTvsGG. Egger’s regression test (P=0.030) B) TTvsGT. Egger’s regression test (P=0.0002) C) TTvsGG. Egger’s regression test (P=0.0006).

**Figure S6**. Funnel plot for the *CYP2B6* rs3745274 meta-analysis in Africans. A) GTvsGG. Egger’s regression test (P=0.979) B) TTvsGT. Egger’s regression test (P=0.106) C) TTvsGG. Egger’s regression test (P=0.063).

**Figure S7**. Funnel plot for the *CYP2B6* rs3745274 meta-analysis in Asians. A) TTvsGG. Egger’s regression test (P=0.049) B) TTvsGT. Egger’s regression test (P=0.068) C) GTvsGG. Egger’s regression test (P=0.206).

**Figure S8.** Funnel plot for the *CYP2B6* rs3745274 meta-analysis in Caucasians. A) TTvsGG. Egger’s regression test (P=0.399) B) TTvsGT. Egger’s regression test (P=0.427) C) GTvsGG. Egger’s regression test (P=0.103).

**Figure S9.** Forest plot of the association between *CYP2A6* rs28399454 and efavirenz plasma concentration. GGvsGA. The center of each square represents the WMD. The area of the square is the number of sample and thus the weight used in the meta-analysis, and the horizontal line indicates the 95% CI.

**Figure S10.** Funnel plot for the *CYP2A6* rs28399454 meta-analysis. GTvsTT. Egger’s regression test (P=0.465).

**Figure S11.** Forest plot of the association between *CYP2A6* rs8192726 and efavirenz plasma concentration. ACvsCC. The center of each square represents the WMD. The area of the square is the number of sample and thus the weight used in the meta-analysis, and the horizontal line indicates the 95% CI.

**Figure S12.** Funnel plot for the *CYP2A6* rs28399433 meta-analysis. GTvsTT. Egger’s regression test (P=0.219).

**Figure S13.** Forest plot of the association between *CYP2A6* rs28399433 and efavirenz plasma concentration. (A)GGvsGT (B)GGvsTT (C)GTvsTT. The center of each square represents the WMD. The area of the square is the number of sample and thus the weight used in the meta-analysis, and the horizontal line indicates the 95% CI.

**Figure S14.** Forest plot of the association between *UGT2B7* rs28365062 and efavirenz plasma concentration. (A)AGvsAA (B)GGvsAA (C)GGvsAG. The center of each square represents the WMD. The area of the square is the number of sample and thus the weight used in the meta-analysis, and the horizontal line indicates the 95% CI.

**Figure S15.** Forest plot of the association between *UGT2B7* rs7439366 and efavirenz plasma concentration. (A)CTvsCC (B)TTvsCC (C)TTvsCT. The center of each square represents the WMD. The area of the square is the number of sample and thus the weight used in the meta-analysis, and the horizontal line indicates the 95% CI.

**Figure S16.** Funnel plot for the *UGT2B7* rs28365062 meta-analysis. A)AAvsAG. Egger’s regression test (P=0.724) B) GGvsAA. Egger’s regression test (P=0.611) C) GGvsAG. Egger’s regression test (P=0.922).

**Figure S17.** Funnel plot for the *UGT2B7* rs7439366 meta-analysis. A) CCvsCT. Egger’s regression test (P=0.399) B) TTvsCC. Egger’s regression test (P=0.291) C) TTvsCT. Egger’s regression test (P=0.698).

**Figure S18.** Forest plot of the association between *UGT2B7* rs3003596 and efavirenz plasma concentration. (A)CCvsCT (B)CCvsTT (C)CTvsTT. The center of each square represents the WMD. The area of the square is the number of sample and thus the weight used in the meta-analysis, and the horizontal line indicates the 95% CI.

**Figure S19.** Funnel plot for the *CAR* rs2307424 meta-analysis. A) CTvsCC. Egger’s regression test (P=0.198) B) TTvsCC. Egger’s regression test (P=0.267) C) TTvsCT. Egger’s regression test (P=0.109).

**Figure S20.** Funnel plot for the *CAR* rs3003596 meta-analysis. A) CTvsCC. Egger’s regression test (P=0.292) B) CTvsTT. Egger’s regression test (P=0.091) C) TTvsCC. Egger’s regression test (P=0.673).

**References**

1. UNAIDS. Fact sheet - Latest statistics on the status of the AIDS epidemic. http://www.unaids.org/en/resources/fact-sheet.

2. Apostolova N, Blas-Garcia A, Galindo MJ *et al*. Efavirenz: What is known about the cellular mechanisms responsible for its adverse effects. *Eur J Pharmacol* 2017; **812**: 163-73.

3. Fumaz CR, Munoz-Moreno JA, Molto J *et al.* Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. *J Acquir Immune Defic Syndr* 2005; **38**: 560-5.

4. Lamorde M, Wang X, Neary M *et al.* Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum. *Clin Infect Dis* 2018; **67**: 785-90.

5. Cerrone M, Wang X, Neary M *et al*. Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals. *Clin Infect Dis* 2019; **68**: 446-52.

6. Ward BA, Gorski JC, Jones DR *et al*. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. *J Pharmacol Exp Ther* 2003; **306**: 287-300.

7. Belanger AS, Caron P, Harvey M *et al*. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. *Drug Metab Dispos* 2009; **37**: 1793-6.

8. Hofmann MH, Blievernicht JK, Klein K *et al*. Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6\*6, is responsible for decreased expression and activity of CYP2B6 in liver. *J Pharmacol Exp Ther* 2008; **325**: 284-92.

9. Haas DW, Ribaudo HJ, Kim RB *et al*. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. *AIDS* 2004; **18**: 2391-400.

10. Rotger M, Colombo S, Furrer H *et al*. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. *Pharmacogenet Genomics* 2005; **15**: 1-5.

11. Nightingale S, Chau TT, Fisher M *et al*. Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G-->T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis. *Antimicrob Agents Chemother* 2016; **60**: 4511-8.

12. Hui KH, Lee SS, Lam TN. Dose Optimization of Efavirenz Based on Individual CYP2B6 Polymorphisms in Chinese Patients Positive for HIV. *CPT Pharmacometrics Syst Pharmacol* 2016; **5**: 182-91.

13. Wyen C, Hendra H, Vogel M *et al*. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. *J Antimicrob Chemother* 2008; **61**: 914-8.

14. Neary M, Owen A. Pharmacogenetic considerations for HIV treatment in different ethnicities: an update. *Expert Opin Drug Metab Toxicol* 2017; **13**: 1169-81.

15. Xu C, Ogburn ET, Guo Y *et al*. Effects of the CYP2B6\*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo. *Drug Metab Dispos* 2012; **40**: 717-25.

16. Ogburn ET, Jones DR, Masters AR *et al*. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. *Drug Metab Dispos* 2010; **38**: 1218-29.

17. Kwara A, Lartey M, Sagoe KW *et al*. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. *AIDS* 2009; **23**: 2101-6.

18. Sarfo FS, Zhang Y, Egan D *et al*. Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. *J Antimicrob Chemother* 2014; **69**: 491-9.

19. Elens L, Vandercam B, Yombi JC *et al*. Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. *Pharmacogenomics* 2010; **11**: 1223-34.

20. Maimbo M, Kiyotani K, Mushiroda T *et al.* CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans. *Eur J Clin Pharmacol* 2012; **68**: 267-71.

21. Cortes CP, Siccardi M, Chaikan A *et al*. Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor. *Ther Drug Monit* 2013; **35**: 78-83.

22. Heil SG, van der Ende ME, Schenk PW *et al*. Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals. *Ther Drug Monit* 2012; **34**: 153-9.

23. Aouri M, Barcelo C, Ternon B *et al.* In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid. *Drug Metab Dispos* 2016; **44**: 151-61.

24. Haas DW, Kwara A, Richardson DM *et al*. Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes. *J Antimicrob Chemother* 2014; **69**: 2175-82.

25. Lamba JK. Pharmacogenetics of the constitutive androstane receptor. *Pharmacogenomics* 2008; **9**: 71-83.

26. Wyen C, Hendra H, Siccardi M *et al*. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. *J Antimicrob Chemother* 2011; **66**: 2092-8.

27. Swart M, Whitehorn H, Ren Y *et al.* PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patients. *BMC Med Genet* 2012; **13**: 112.

28. Swart M, Evans J, Skelton M *et al*. An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients. *Front Genet* 2015; **6**: 356.

29. Olagunju A, Bolaji O, Amara A *et al.* Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study. *Clin Infect Dis* 2015; **61**: 453-63.

30. Liberati A, Altman DG, Tetzlaff J *et al*. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Med* 2009; **6**: e1000100.

31. Wan X, Wang W, Liu J *et al*. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol* 2014; **14**: 135.

32. Jorgensen AL, Williamson PR. Methodological quality of pharmacogenetic studies: issues of concern. *Stat Med* 2008; **27**: 6547-69.

33. (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

34. Borenstein M, Hedges, L., Higgins, J. *et al.* Comprehensive Meta-Analysis Biostat, Englewood, NJ, 2013.

35. Wallace BC, Issa J. Dahabreh, Thomas A. Trikalinos *et al*. Closing the Gap between Methodologists and End-Users: R as a Computational Back-End. *J Stat Softw* 2012; **49**: 5.

36. Bienczak A, Cook A, Wiesner L *et al*. The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children. *Br J Clin Pharmacol* 2016; **82**: 185-98.

37. Sandkovsky U, Podany AT, Fletcher CV *et al*. Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients. *J Antimicrob Chemother* 2017; **72**: 200-4.

38. Dhoro M, Zvada S, Ngara B *et al*. CYP2B6\*6, CYP2B6\*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe. *BMC Pharmacol Toxicol* 2015; **16**: 4.

39. Olagunju A, Siccardi M, Amara A *et al*. CYP2B6 516G>T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients. *Ther Drug Monit* 2014; **36**: 734-8.

40. Tsuchiya K, Gatanaga H, Tachikawa N *et al*. Homozygous CYP2B6 \*6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. *Biochem Biophys Res Commun* 2004; **319**: 1322-6.

41. Wang J, Sonnerborg A, Rane A *et al.* Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. *Pharmacogenet Genomics* 2006; **16**: 191-8.

42. Gatanaga H, Hayashida T, Tsuchiya K *et al.* Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 \*6 and \*26. *Clin Infect Dis* 2007; **45**: 1230-7.

43. Uttayamakul S, Likanonsakul S, Manosuthi W *et al*. Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults. *AIDS Res Ther* 2010; **7**: 8.

44. Gounden V, van Niekerk C, Snyman T *et al*. Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. *AIDS Res Ther* 2010; **7**: 32.

45. Habtewold A, Amogne W, Makonnen E *et al*. Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. *J Antimicrob Chemother* 2011; **66**: 2350-61.

46. Sukasem C, Cressey TR, Prapaithong P *et al*. Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults. *Br J Clin Pharmacol* 2012; **74**: 1005-12.

47. Mutwa PR, Fillekes Q, Malgaz M *et al*. Mid-dosing interval efavirenz plasma concentrations in HIV-1-infected children in Rwanda: treatment efficacy, tolerability, adherence, and the influence of CYP2B6 polymorphisms. *J Acquir Immune Defic Syndr* 2012; **60**: 400-4.

48. Sukasem C, Chamnanphon M, Koomdee N *et al*. High plasma efavirenz concentration and CYP2B6 polymorphisms in Thai HIV-1 infections. *Drug Metab Pharmacokinet* 2013; **28**: 391-7.

49. Bienvenu E, Swart M, Dandara C *et al.* The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients. *Antiviral Res* 2014; **102**: 44-53.

50. Sukasem C, Chamnanphon M, Koomdee N *et al*. Pharmacogenetics and clinical biomarkers for subtherapeutic plasma efavirenz concentration in HIV-1 infected Thai adults. *Drug Metab Pharmacokinet* 2014; **29**: 289-95.

51. Dickinson L, Amin J, Else L *et al.* Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naive HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study. *Clin Pharmacokinet* 2016; **55**: 861-73.

52. Cusato J, Tomasello C, Simiele M *et al.* Efavirenz pharmacogenetics in a cohort of Italian patients. *Int J Antimicrob Agents* 2016; **47**: 117-23.

53. Neary M, Lamorde M, Olagunju A *et al*. The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine. *Clin Pharmacol Ther* 2017; **102**: 529-36.

54. Swart M, Skelton M, Ren Y *et al*. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients. *Pharmacogenet Genomics* 2013; **23**: 415-27.

55. Klein K, Lang T, Saussele T *et al*. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. *Pharmacogenet Genomics* 2005; **15**: 861-73.

56. Rotger M, Tegude H, Colombo S *et al*. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. . *Clin Pharmacol Ther* 2007; **81**: 557-66.

57. Sinxadi PZ, Leger PD, McIlleron HM *et al*. Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa. *Br J Clin Pharmacol* 2015; **80**: 146-56.

58. Mulugeta A EA, Belew Y. Genetic variability of CYP2B6 G516T and their impact in efavirenz based HAART: A meta-analysis. *Int J Pharm Sci Res* 2012; **3**:763-772.

59. Ribaudo HJ, Liu H, Schwab M *et al.* Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. *J Infect Dis* 2010; **202**: 717-22.

60. Group ES. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. *Lancet* 2014; **383**: 1474-82.

61. Olagunju A, Schipani A, Bolaji O *et al*. Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling. *J Antimicrob Chemother* 2018; **73**: 165-72.

62. di Iulio J, Fayet A, Arab-Alameddine M *et al*. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. *Pharmacogenet Genomics* 2009; **19**: 300-9.

63. Sueyoshi T, Kawamoto T, Zelko I *et al*. The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. *J Biol Chem* 1999; **274**: 6043-6.

64. Nuñez M, Gonzalez de Requena D, Gallego L *et al*. Higher efavirenz plasma levels correlate with development of insomnia. *J Acquir Immune Defic Syndr* 2001; **28**: 399-400.

65. Clifford DB, Evans S, Yang Y *et al*. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. *Ann Intern Med* 2005; **143**: 714-21.

66. Gallego L, Barreiro P, del Rio R *et al*. Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz. *Clin Infect Dis* 2004; **38**: 430-2.

67. Ikeda S, Kurose K, Jinno H *et al*. Functional analysis of four naturally occurring variants of human constitutive androstane receptor. *Mol Genet Metab* 2005; **86**: 314-9.